[go: up one dir, main page]

MX2013002927A - Inhibidores del virus de la hepatitis c. - Google Patents

Inhibidores del virus de la hepatitis c.

Info

Publication number
MX2013002927A
MX2013002927A MX2013002927A MX2013002927A MX2013002927A MX 2013002927 A MX2013002927 A MX 2013002927A MX 2013002927 A MX2013002927 A MX 2013002927A MX 2013002927 A MX2013002927 A MX 2013002927A MX 2013002927 A MX2013002927 A MX 2013002927A
Authority
MX
Mexico
Prior art keywords
hepatitis
novel compounds
virus inhibitors
compounds
disclosure
Prior art date
Application number
MX2013002927A
Other languages
English (en)
Inventor
Makonen Belema
Piyasena Hewawasam
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2013002927A publication Critical patent/MX2013002927A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta invención se refiere a novedosos compuestos de la fórmula (I) (Ver Formula) como los definidos en la descripción, y a composiciones que comprenden estos compuestos novedosos. Estos compuestos son agentes antivirales útiles, especialmente para inhibir la función de la proteína NS5A codificada por el virus de la hepatitis O (HCV). De esta manera, la invención se refiere también a un método para tratar enfermedades o afecciones relacionadas con HCV mediante el uso de estos compuestos novedosos o a una composición que comprende estos compuestos novedosos.
MX2013002927A 2010-09-24 2010-09-24 Inhibidores del virus de la hepatitis c. MX2013002927A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/050138 WO2012039717A1 (en) 2010-09-24 2010-09-24 Hepatitis c virus inhibitors

Publications (1)

Publication Number Publication Date
MX2013002927A true MX2013002927A (es) 2013-05-30

Family

ID=43037168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002927A MX2013002927A (es) 2010-09-24 2010-09-24 Inhibidores del virus de la hepatitis c.

Country Status (8)

Country Link
EP (1) EP2619195A1 (es)
JP (1) JP5619289B2 (es)
CN (1) CN103249730A (es)
BR (1) BR112013008148A2 (es)
CA (1) CA2812699A1 (es)
EA (1) EA201370078A1 (es)
MX (1) MX2013002927A (es)
WO (1) WO2012039717A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2565536T3 (es) 2009-06-11 2016-04-05 Abbvie Bahamas Ltd. Heterociclos trisustituidos como inhibidores de la replicación del virus de la Hepatitis C VHC
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
CA2767887A1 (en) 2009-07-16 2011-01-20 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
JP2013522375A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
CA2809261A1 (en) 2010-08-26 2012-03-01 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis c virus
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
IN2014MN01547A (es) 2012-02-10 2015-05-08 Lupin Ltd
TWI510481B (zh) 2012-06-04 2015-12-01 Actelion Pharmaceuticals Ltd 苯并咪唑脯胺酸衍生物
EA201500399A1 (ru) 2012-10-10 2015-09-30 Актелион Фармасьютиклз Лтд. Антагонисты рецептора орексина, которые представляют собой производные [орто-би-(гетеро)арил]-[2-(мета-би-(гетеро)арил)пирролидин-1-ил]метанона
EP2970241A1 (en) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
AU2014358766B2 (en) 2013-12-04 2019-01-17 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US11974572B2 (en) 2017-03-31 2024-05-07 Sygenta Participations Ag Fungicidal compositions
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
KR20210139270A (ko) 2019-03-15 2021-11-22 메드임뮨 리미티드 암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트
WO2024259085A2 (en) * 2023-06-14 2024-12-19 Alexion Pharmaceuticals, Inc. Methods for the synthesis of complement factor d inhibitors and intermediates thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7183302B2 (en) 2002-08-12 2007-02-27 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of HCV replication
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DE102004036971B4 (de) 2004-07-30 2009-07-30 Advanced Micro Devices, Inc., Sunnyvale Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2010034721A (ja) * 2008-07-28 2010-02-12 Fujitsu Ltd パケットキャプチャ装置，パケットキャプチャ方法およびパケットキャプチャプログラム
CA2745119A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8796466B2 (en) * 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) * 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
BR112013008148A2 (pt) 2016-08-09
JP2013537905A (ja) 2013-10-07
CA2812699A1 (en) 2012-03-29
WO2012039717A1 (en) 2012-03-29
CN103249730A (zh) 2013-08-14
EA201370078A1 (ru) 2013-11-29
JP5619289B2 (ja) 2014-11-05
EP2619195A1 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
MX2011009644A (es) Inhibidores del virus de la hepatitis c.
MX2013002927A (es) Inhibidores del virus de la hepatitis c.
EA201171152A1 (ru) Ингибиторы вируса гепатита c
MX2010002904A (es) N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
SI1987038T1 (sl) Hcv ns5b inhibitorji
PL2209789T3 (pl) Skondensowane z cyklopropylem indolobenzoazepinowe inhibitory NS5B HCV
EP2600835A4 (en) COMBINATIONS OF INHIBITORS OF HEPATITIS C VIRUS
MX2009004888A (es) Inhibidores del virus de la hepatitis c.
EA201270555A1 (ru) Комбинации ингибиторов вируса гепатита с
MX2009004943A (es) Inhibidores del virus de la hepatitis c.
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
WO2013074386A3 (en) Hcv ns3 protease inhibitors
MX2014008227A (es) Inhibidores del virus de la hepatitis c.
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007140254A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
NO20091845L (no) Macrocykliske peptider som hepatitt C virus-inhibitorer
PH12013502190A1 (en) Hepatitis c virus inhibitors
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c
EA201391717A1 (ru) Ингибиторы вируса гепатита с
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
MX2013004464A (es) Inhibidores de polimerasa viral.
MX2010010235A (es) Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a pirrolidina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal